Home / Transcripts / MetLife, Inc. (MET) · November 5, 2026

MetLife, Inc. (MET) Earnings Call Transcript & Summary

November 5, 2026

New York Stock Exchange US Financials Insurance earnings 61 min

What were the key takeaways from MetLife, Inc.'s November 5, 2026 earnings call?

In the third quarter of 2026, MetLife, Inc. reported strong financial results, with adjusted earnings of $1.8 billion, translating to an adjusted EPS of $2.85, up 22% year-over-year. The company experienced broad-based growth across all operating segments, driven by significant contributions from variable investment income, particularly in private equity and venture capital. Management raised guidance for Retirement and Income Solutions (RIS), expecting adjusted earnings to finish slightly north of the midpoint of the $1.6 billion to $1.8 billion range. This performance reinforces the effectiveness of MetLife's New Frontier strategy, which emphasizes disciplined capital management and diversified growth.

What topics did MetLife, Inc. cover?

What were MetLife, Inc.'s November 5, 2026 results?

MetLife's strong Q3 results underscore the effectiveness of its New Frontier strategy, with broad-based growth and disciplined capital management. The company is well-positioned for continued success, but analysts are cautious about potential normalization in mortality trends and the sustainability of recent performance improvements. Investors should monitor future earnings guidance and capital management strategies as key indicators of MetLife's ongoing growth trajectory.

Earnings Call Speaker Segments

John Hall executive
#1

Thanks, operator, and good morning to all of you. It's a pleasure to welcome you to the earnings call for MetLife's third quarter of 2026. First, we'd ask that you take a look at the details on non-GAAP measures contained in our earnings release, our quarterly financial supplement, and the earnings call and investor presentations — you'll find all of these posted on the investor relations website, metlife.com. Joining us today are Michel Khalaf, our President and Chief Executive Officer, along with John McCallion, Chief Financial Officer and Head of MetLife Investment Management. Several other members of senior management are here as well and available to take part. This morning, John will walk through the earnings call presentation that we posted last night on our website. You should review the appendix to that deck, which includes disclosures, GAAP reconciliations, and other information. Once the prepared remarks are done, we'll hold a Q&A session that wraps up at the top of the hour. One reminder: please keep to one question and one follow-up. I'll now hand things over to Michel.

Michel Khalaf executive
#2

Appreciate that, John, and morning to everybody. The third quarter proved another outstanding stretch under our New Frontier strategy. We achieved the greatest quarterly adjusted EPS in MetLife history, and every operating segment delivered top-line expansion. What matters even more is that this period continues a trend visible throughout the year: wide-ranging growth, appealing returns, and prudent capital stewardship. Variable investment income added a great deal this quarter, particularly from private equity and venture capital results. VII lifted the quarter but did not characterize it; we likewise generated robust underwriting and volume gains across the company. No individual unit powered these results. Such breadth represents MetLife's core advantage. Our complementary capital-light and capital-driven earnings engines enable us to generate value through differing approaches and in varying market conditions. Our underwriting margins, along with fees and spread income, generate durable earnings and recurring cash flow. That cash gets reinvested in areas where MetLife enjoys structural advantages, and we also return surplus capital to shareholders. These engines strengthen each other as well. In our retirement businesses, we originate liabilities that are backed by long-term assets, and we draw on insurance and third-party capital to fund that expansion. MetLife Investment Management oversees the bulk of those assets, which adds fee income and grows our capital-light earnings. This efficient model helps drive growth and produce capital for reinvestment. It is a model built to compound. Two years into New Frontier, the evidence that the strategy is working as intended is increasingly clear. So far this year, adjusted EPS — leaving out notable items — has climbed 22%, and adjusted return on equity stands above 17%. Growth drivers shift between quarters, yet the overall shape stays consistent: execution across the board, appealing returns, and robust cash generation. Turning to the third-quarter figures: adjusted earnings came in at $1.8 billion, equal to $2.78 per share. That figure includes $46 million in notable items, mostly tied to our yearly actuarial assumption review. Once notable items are excluded, adjusted earnings were $1.8 billion, a 17% increase, while adjusted earnings per share reached $2.85, up 22%, each compared with a year earlier. Variable investment income was $720 million pre-tax, generated on private equity returns exceeding 4%, against 3% in the prior-year period. Direct expense ratio came in at 11.9%, and we're on track to outperform our full-year goal of 12.1%. Productivity plays a major role in that, with AI contributing more and more. For us, AI acts as a force multiplier—it supports growth, enhances the customer experience, and lets us work faster and more precisely, all while keeping our ratio contained as we take on PineBridge Investments, a business with structurally higher expenses. Adjusted return on equity, excluding notable items, reached 19.6%, comfortably surpassing our full-year target range of 15%-17%. That's what compounding looks like: we generate a high return on equity, return capital to shareholders, and still increase adjusted book value per share, which rose 5% year over year to $59.41. Moving on to how our businesses performed, beginning with group benefits: adjusted earnings reached $523 million excluding notables, which is a 14% increase. Life underwriting benefited from continued broad-based gains in working-age mortality. Our group life mortality ratio was 79.5%, well within our target range. On non-medical health, the ratio was 72.3%, a bit below the middle of our target range. Adjusted premiums, fees and other revenues — PFOs — grew 5% when participating contracts are excluded, and sales have climbed 12% year to date. In my opinion, group benefits is the most appealing segment in U.S. life insurance, and MetLife stands far and away as the leader across the industry's broadest set of products and markets. That kind of unmatched size produces growth that beats the market, with nearly $26 billion in yearly PFO. These PFOs need little capital and turn into adjusted earnings with a strong rate of free cash flow conversion. Moving to Retirement and Income Solutions, or RIS, adjusted earnings aside from notable items came to $478 million, a 12% rise thanks to better investment margins and more volume. Adjusted PFOs, leaving out pension risk transfers, climbed 33%, helped in part by U.K. longevity reinsurance, and retained liability balances gained 7%. U.S. pension risk transfer activity has been slower this year, but we view that as a matter of timing rather than a structural shift. Plan sponsors have execution flexibility around timing and structure thanks to strong funding levels, and the desire to reduce risk stays robust—these are all major findings from our yearly poll of plan sponsors on pension risk transfer. That points to a fundamental strength of our retirement operation: its breadth across multiple channels and products. Beyond PRT, we hold leading positions in UK longevity reinsurance, UK funded reinsurance, structured settlements, stable value, and corporate-owned life insurance, and our U.S. retail annuity reinsurance business keeps expanding. Because our reach is wide and our positions are strong, no single retirement market carries our fortunes, and we can shift toward the opportunities offering the greatest and best use of our capital. In Asia, adjusted earnings excluding notable items came to $550 million, a 21% increase on a constant currency basis. Higher VII and favorable equity markets performance both contributed to the results. Adjusted PFOs were up 5% on a constant currency basis, and Korea continues to demonstrate strong momentum. Turning to Latin America, adjusted earnings excluding notable items were $229 million. Market conditions in Chile affected the result, producing a negative encaje return. Our momentum is what stands out here. Adjusted PFOs rose 14% on a constant currency basis, with Mexico and Chile leading the way. As the number one life insurer in Latin America, we serve roughly 30 million customers through group, agency, and direct channels, including our Xcelerator embedded insurance platform. In EMEA, adjusted earnings came in at $114 million excluding notable items, a 30% increase. That exceeded the $90 million to $100 million quarterly run rate we've talked about, and volume growth was the driver. Adjusted PFOs rose 17% on a constant currency basis. Embedded insurance is delivering results here as well. Through our new multi-market partnership with Revolut, among Europe's biggest digital banks, customers get a seamless, integrated experience; it's part of a broader story about MetLife's ability to apply its capabilities globally. The digital lessons we've learned, together with the capabilities and experience built in Latin America, in EMEA, and soon in Asia too, are being put to work — which demonstrates what One MetLife can achieve. At MetLife Investment Management, or MIM, adjusted earnings reached $63 million, up 9%, and 19% year to date, thanks to folding in PineBridge and a sequential gain in profit margin. No one business drove the quarter. Group stood out on underwriting, RIS and Asia on investments, and Latin America and EMEA on top-line growth — that's diversification at work, and it shows how our results endure across all kinds of conditions. Given a favorable environment for the life insurance sector — higher rates, stable credit, and rising demand for retirement products — our solid capital base creates many appealing paths for growth. The foundation of everything is the reliable recurring capital we generate along with our free cash flow, combined with a rigorous approach to putting that capital to work. Priority number one is organic growth, since that's where we enjoy structural advantages and where we can achieve appealing returns relative to risk. Any dollar committed to backing new business must clear a demanding return threshold, and we monitor the value it produces — VNB, meaning the value of new business. This is something we've maintained without interruption for over ten years.

Michel Khalaf executive
#3

When we began this effort a decade ago, we committed $2.9 billion of capital at a 12% internal rate of return with an eight-year payback period. If we jump ahead to last year, we put $3.8 billion to work at a 19% IRR and a five-year payback. So we deployed more capital, earned a higher IRR, and recovered it faster. That discipline keeps compounding, and you can see it reflected in our rising return on equity. Once we have funded attractive organic growth, we look at acquisitions, but only if they bring a strategic capability and satisfy our stringent financial criteria. When we consider any deal, it has to deliver at least the return we'd get from putting money into our own operations or buying back our stock. Beyond those options, our practice is to return surplus capital to shareholders consistently. In Q3 we repurchased $650 million of common shares, and we bought back an additional $265 million in October. Through buybacks and common stock dividends combined, capital returned to shareholders so far this year comes to about $3.5 billion. Liquidity remains robust: holding company cash and liquid assets stood at $3.4 billion when the quarter ended. To wrap up, the recurring revenue model under New Frontier is performing at full strength across every part of the business. We own market-leading businesses, two earnings engines that complement each other, and we take a disciplined approach to allocating capital. All of that combines to give us sustainable profits, free cash flow that keeps coming back, and several paths toward growth that pays off. Our board of directors routinely stress-tests the strategy alongside us, and in the third quarter we did a deep dive of that kind; the exercise left us more convinced than ever about New Frontier and about MetLife's position as a quality compounder — a company that can produce earnings growth others can't match, appealing returns, and a steady flow of capital back to shareholders. Yes, this quarter set a record, but what matters more is the pattern underneath it. The model is delivering, growth is spreading across more of the business, and we're executing with discipline. That said, I'll hand things to John, who will take you through the results in greater detail.

John McCallion executive
#4

Thanks, Michel, and good morning to all of you. As Michel laid out, we keep seeing robust momentum throughout the enterprise, and what really stands out is how good that growth is. We're producing appealing returns, holding the line on expenses, and putting capital to work in opportunities that build long-term value. Those are key hallmarks of our model; they let us invest in growth, produce robust free cash flow, and give excess capital back to shareholders, all while keeping a strong balance sheet. I'll walk you through what we delivered in the third quarter, then dig into a few of the proof points underlying those numbers — our expense discipline, the returns we're generating on new business, the quality of our investment portfolio, and where we stand on cash and capital. Starting on page three, we beat our key financial commitments once again. Adjusted EPS, excluding notable items, was up 22%, well ahead of our double-digit target. Adjusted ROE, excluding notables, reached 19.6%, putting us on track to exceed our annual target range of 15%-17%. Our direct expense ratio came in at 11.9%, which keeps us on pace to beat our 12.1% annual target. Importantly, these results build on strong performance all year long. So far this year, adjusted EPS — leaving out notable items — has climbed 22%, and adjusted ROE stands at more than 17%. In the quarter, net income was $2.4 billion, equal to $3.67 per share. Adjusted earnings totaled $1.8 billion, or $2.78 per share. Net income landed roughly $570 million higher than adjusted earnings, largely driven by a non-economic accounting gain that followed interest rates rising over the quarter. The remaining gap comes from net investment losses, which include routine trading activity, partly offset by gains on market risk benefits. Our credit outlook remains stable. If you turn to page four, I'll walk through a bit more detail on those notable items Michel Khalaf brought up. During the third quarter, as is our custom, we wrapped up the yearly worldwide actuarial assumption review, and its overall effect was modest. That review, together with the other insurance adjustments you can see on page four, reduced adjusted earnings by $46 million, equal to $0.07 per share. At Retirement and Income Solutions, or RIS, there was an unfavorable hit from lower mortality, and that was mostly offset by favorable economic and mortality updates in Asia. Turning now to page five, let's look at how the underlying business performed; every comparison in this section is year-over-year and leaves out total notable items. Adjusted earnings rose 17% to $1.8 billion, powered by higher variable investment income, or VII, volume growth, and favorable underwriting. That gain was partly offset by higher expenses, primarily employee-related costs. Adjusted EPS rose 22% to $2.85, helped along by disciplined capital management. Turning to Group Benefits, adjusted earnings reached $523 million, a 14% increase, largely on the strength of favorable underwriting. At 79.5%, the group life mortality ratio came in under our 2026 target range of 83%-88% and improved on last year's 83.4%. Mortality for the working-age population remained favorable; for non-medical health, the interest-adjusted benefit ratio stood at 72.3%, inside our 70%-75% target range. That marked a 160 basis point improvement over the prior quarter, in line with seasonal dental utilization. Growth was healthy as well. Adjusted PFOs were 3% higher, or 5% higher excluding participating contracts, and year-to-date sales rose 12%, fueled by strong performance in both national accounts and regional business. Over in RIS, adjusted earnings reached $478 million, a 12% gain, helped along by better investment margins and growth in volume. Private equity returns came in stronger, which pushed the total investment spread up to 130 basis points — above the 100 to 120 basis point guidance range we'd given. Core spread, which excludes VII, landed at 99 basis points, right where we expected. Adjusted PFOs, leaving out pension risk transfers, jumped 33%, largely on the back of increased sales of post-retirement benefits and U.K. longevity reinsurance. Total retained liability exposures expanded 7%, topping our 3%-5% outlook range. With the business performing as it has so far this year, and assuming normal VII in the fourth quarter, we're looking for full year RIS adjusted earnings to land a bit above the midpoint of our $1.6 billion-$1.8 billion outlook range. In Asia, adjusted earnings were $550 million, up 17%, or 21% in constant currency terms. The main thing behind that was higher VII. Favorable equity markets and volume growth also fed into the strong result; those gains were partly offset by underwriting that was less favorable against a particularly strong quarter a year earlier. General account assets under management at amortized cost grew 4% in constant currency. In Asia, constant-currency sales dropped 6%, coming off a tough comparison with the prior year. Even so, year-to-date constant-currency sales have climbed 10%, led by Japan and Korea. Now for Latin America: adjusted earnings came in at $229 million, a 3% increase, which translates to a 5% decline in constant currency. We saw solid volume growth, but it was mostly offset by a weaker encaje return — negative 3% versus a positive 6% in last year's same period — amounting to a roughly $30 million year-over-year headwind. Regional top-line momentum remained robust and broad-based, as adjusted PFOs grew 22%, or 14% in constant currency, while sales rose 6% in constant currency. In EMEA, adjusted earnings rose 30% to $114 million—37% in constant currency—thanks to volume growth. The region's continued expansion powered a 14% increase in adjusted PFO (17% in constant currency), supported by strong sales momentum and healthy renewal activity. Constant-currency sales grew 16%. As the business scales, that growth is translating into earnings that are increasingly steady and durable. At MetLife Investment Management, or MIM, adjusted earnings reached $63 million, a 9% gain driven by business growth, including the PineBridge addition. Total AUM came to $723 billion, up 14%, with institutional client AUM of $308 billion, 45% higher than a year earlier. Sequentially, total AUM fell by $25 billion, driven largely by mark-to-market effects from higher rates on public fixed income; for the full year, we still expect adjusted earnings to land inside our $240 million to $280 million target range. Lastly, Corporate & Other recorded an adjusted loss of $131 million, versus a loss of $159 million in the prior-year period. A bigger VII, combined with lower preferred dividends—reflecting the Series G preferred stock redemption completed last year—more than offset higher employee-related costs. On adjusted earnings for the quarter, the effective tax rate was 23%, slightly below the 24%-26% range we guided for 2026. On page six, you'll find a five-quarter view of pre-tax VII. VII reached $720 million in the third quarter, far ahead of the roughly $400 million quarterly figure implied by our guidance. Just as we expected three months ago, the beat came from stronger private equity returns. Returns averaged 4.2%, with venture capital leading the way on the back of robust IPO activity and public market valuations. Keep in mind that private equity as well as real estate and other funds get reported on a one-quarter lag and on a mark-to-market basis. VII so far this year stands at about $1.5 billion, which keeps us on track to beat our roughly $1.6 billion full-year guidance. Page seven breaks out post-tax VII by business segment and Corporate & Other. By the end of September 30th, VII assets totaled $18.8 billion, with 48% allocated to Asia, 26% to RIS, and 22% to Corporate & Other. Each business maintains a distinct portfolio designed to align with the long-term nature of its obligations. On page eight, the direct expense ratio for Q3 stood at 11.9%, compared with 11.6% in the prior-year period and 11.7% for the full year 2025.

Ramy Tadros executive
#5

So far this year, that ratio sits at 12%, which is under our 12.1% target, even while we're absorbing about 50 basis points tied to PineBridge. Solid PFO growth along with ongoing expense discipline — including productivity gains driven by AI and technology — is helping to counterbalance higher costs related to employees. Our expense management is done on a full-year basis, and we're still on course to exceed our target. Let me move to page nine, since this touches on a key element of our capital allocation narrative — not just the amount we grow, but the value we generate from the capital we put to work. During 2025, we put $3.8 billion of capital to work and produced $2.8 billion in value of new business, or VNB, which is 8% higher than 2024, with new business premium growth across every segment; for a third consecutive year, we delivered a 19% internal rate of return and a five-year payback. Relative to 2021, that's 2 points better on IRR and 1 year quicker on payback. Across that stretch, VNB rose 50%, from $1.9 billion to $2.8 billion, while capital deployed grew by only roughly one-third, from $2.8 billion to $3.8 billion. We're producing more value out of every dollar of capital deployed. That's the capital efficiency we care about. It also generates a self-reinforcing cycle. Attractive returns and quicker payback underpin capital generation; that capital can then finance the next round of attractive growth or be handed back to shareholders. Adjusted ROE, excluding notables, stands above 17% year to date. Free cash flow ratio for last year came in above the top end of our 65%-75% target. Our approach is simple. We pursue opportunities when returns clear our hurdles, and we stay disciplined when they don't. That same emphasis on risk-adjusted returns carries over to our investment portfolio. I'd like to spend a moment on our exposure to AI-related infrastructure, given the growing attention this area is getting; on page 10, beginning at the left, our hyperscaler exposure comes to $1.6 billion. The bulk of it, $1.4 billion, is public fixed income, and the remaining $200 million is private fixed income. All of the hyperscaler exposure is investment grade, rated Aa3 on average, with a weighted average life of roughly 17 years; on the right, our data center exposure comes to $2.5 billion. Roughly half, $1.3 billion, is private fixed income, then public fixed income of $1 billion, and real estate accounts for approximately $200 million. More than 95% of the fixed income is investment grade, and weighted average life is around four years. Taken together, our exposures come to $4.1 billion. Every category accounts for under 1% of our general account, so this is a modest exposure against the overall portfolio. What really matters here is that neither category shows any delinquencies or impairments. In short, these exposures are high quality and diversified, and they're modest in size compared with our balance sheet. When the opportunity set shifts, we'll continue applying the same disciplined underwriting and risk-adjusted return standards we use across the entire portfolio. Let's now turn to capital and liquidity on page 11. We continue to operate from a strong position, which gives us room to fund attractive growth while also returning surplus capital to shareholders. By the end of September 30th, the holding company held $3.4 billion in cash and liquid assets, which falls within our target buffer of $3 billion to $4 billion; during the third quarter we returned about $1 billion to shareholders, comprising $380 million in common dividends and $650 million in share repurchases. In October we repurchased another $265 million of shares, taking year-to-date buybacks through October to $2.4 billion. Our capital allocation framework remains the same, and the strength of our capital and liquidity allows us to execute against it. At our U.S. companies, we estimate total statutory adjusted capital on an NAIC basis at roughly $17 billion as of September 30th, a 3% increase from June 30th. Finally, turning to Japan: for the fiscal year that concluded on March 31, 2026, our economic solvency ratio, or ESR, came in at 192%. That sits just a touch above the upper bound of the 170%–190% range we talked about earlier. I'll wrap up with three points. First, the quality and breadth of our growth were reinforced this quarter; we posted robust underlying results throughout the enterprise, and diversification keeps providing us with multiple avenues for earnings growth. Second, our emphasis is on making that growth more valuable over time. Cost discipline, solid returns on new business, and gains in capital efficiency are all helping us convert growth into better returns and powerful cash generation. Third, the strength of our balance sheet and our liquidity means we can continue putting money to work wherever we spot appealing opportunities, even as we keep returning surplus capital to shareholders. All of that together is how we view New Frontier's capacity to build long-term value. Sustained growth, appealing returns, prudent capital allocation, and the financial room to keep compounding — we're happy with where we stand and sure of our capacity to meet our 2026 commitments and our longer-term goals. Having said that, I'll hand the call back to the operator so we can take your questions.

Ryan Krueger analyst
#6

Hi there, thanks. Good morning. I'd like to begin with non-medical health. Could you break down the loss ratio for the quarter in a bit more detail, separating disability from dental? I'm certain you've noticed that a lot of businesses in this sector have posted softer disability outcomes, so I wanted to grasp how that affected Met, and then, apart from that, what you observed on the dental side.

Ramy Tadros executive
#7

Good morning, Ryan. Ramy speaking. Let me start off by saying that for the quarter, we're quite happy with our group results overall, with strong year-over-year improvement on both the top line and the bottom line. Our non-medical health ratio forms part of that, and just as you mentioned, it does take in disability; that figure, as you can see, sits squarely within our guidance range too. I’ll break that down for you, beginning with disability. During the quarter, disability had both positive and negative elements; we observed a modest rise in severity. Other factors balanced that out, among them fairly strong recoveries on claim closures, which come straight from the ongoing investments we make in that area—so we’re truly happy with the results. On the whole, incidence remains largely in line with our expectations. As we entered 2026, we had anticipated and planned for a rise in incidents, and we did observe growth in claim submissions, and specifically, we saw mental nervous claims climb across the year; but once again, taken as a whole, the results are broadly in line. As you look ahead and consider disability along with the broader non-medical health ratio, well, disability is a line that the macro environment could affect. We'll keep watching this closely and stay proactive about putting every right lever in place so we remain within our target margins, and you saw us do exactly that this year. Another point I'd add, just to build on the dental piece, is that diversification matters; we're gaining from the actions, pricing, and network growth we've delivered on dental with respect to our loss ratio there. Disability represents roughly 15% of our premiums. Putting all of that together, we believe we're really well-positioned as we head into the future.

Ryan Krueger analyst
#8

Thanks. Then, about expenses. I believe stock compensation related to your stock move had a somewhat negative effect on them. Could you quantify that for us, simply to help us grasp how it affected results?

John McCallion executive
#9

Hey, Ryan. This is John. Good morning. It was likely around one or two points on the expense ratio. So overall, as you mentioned, we saw a rise in incentive comp as we entered the quarter, so it's likely, as I said, roughly one or two points on the expense ratio is probably the best guide.

Ryan Krueger analyst
#10

Okay, thanks. A good problem to have.

Suneet Kamath analyst
#11

Thanks. Good morning. Just regarding group life, we've observed this working age mortality phenomenon keep helping the industry overall and you guys too. Is your feeling that, and again, I think we've discussed this before, that part of it might be COVID pull forward and similar factors, but is your sense that we're kind of at the point where it's run its course, or would you anticipate that this favorability might persist, and when does it kind of get factored into pricing? Thanks.

Ramy Tadros executive
#12

Hey, Suneet. This is Ramy. Good morning. Look, predicting this is very difficult. Various potential drivers exist for the favorability. There are pull forward effects, and there are other sorts of contributors there. But how I would think about it as it relates to our financial results is this is a competitive market, and if these trends persist, we would anticipate the favorability to progressively normalize over time, but progressively being the key word here; we have a business that's largely national accounts skewed, and the renewal cycle is three to five years. So think of this progressive normalization occurring over a period of years rather than quarters. The other point I'll make for you is, we've had a really strong outcome this year; it wasn't just all population. We had a mild flu season in Q1. We've now had two quarters of lower severity, which I wouldn't necessarily trend. So looking at the very near term, think Q4 and Q1, we would anticipate a seasonal uptick in both of those quarters, largely driven by normal flu seasonality. So think of that as the short-term dynamic and juxtapose it with the long-term dynamic I just talked about earlier.

Suneet Kamath analyst
#13

Okay, that helps. Then I suppose for John regarding the VNB figures, if we look across a somewhat longer stretch than what appears on your slide, I believe you're up roughly 500 basis points on IRR across the last 10 years. And I'm curious whether you've done any analysis on what the components of that gain have been, or what has driven it — how much came from interest rates, how much from mix, how much from cost — just so we can gauge how sustainable today's levels are. Thanks.

John McCallion executive
#14

Yeah, appreciate the question, Suneet. John here. Yeah, being really precise on that is probably tough. You're correct, it's likely 500 basis points, perhaps even more, but if you set it against when we ultimately first began. What I'd say is, if we step back and consider the largest driver, it was giving our leaders the tools to make sound decisions holistically on matters such as product design, as you mentioned, and expense management, since you witness the power of unit costs and the present value of those benefits flowing through. Interest rates play a part, as you point out. So we have observed some of that; thus, I'd probably feel fairly balanced across all those elements regarding what the contributions have been. Overall, probably, as I said, the most significant thing has been culturally and from a DNA standpoint, placing those tools and that value-driven mindset in our leaders' hands has probably been the largest driver of the change.

Suneet Kamath analyst
#15

So, presumably fairly sustainable then?

John McCallion executive
#16

Yes, that's our belief. I think another point worth highlighting is, we've also observed our mix, and we've discussed, and Michel opened with this around, and how we're describing these two complementary engines; we've seen a rising mix of capital light. We still prefer our capital-driven businesses, and we feel there are solid growth opportunities there too. From a mix standpoint, we are seeing a higher ROE set of businesses account for a larger share of our earnings. Then also keep in mind, there's been an accelerated runoff of our legacy retail business, which carries a lower ROE. All of those elements are feeding into the sustainability.

Suneet Kamath analyst
#17

Okay. Thanks.

Tom Gallagher analyst
#18

Thanks. First question for Ramy. How do you expect this pricing for disability situation to unfold given recent elevated claims at competitors? You mentioned your own claims are somewhat elevated, because claims are elevated, but the ROEs in the business remain very good, I believe. Should we view it as perhaps a soft market offsetting on pricing, or do you think this actually hardens the market and we begin to see rate increases here?

Ramy Tadros executive
#19

Thanks, Tom. Look, as an industry, we've always maintained—and we still view it this way—that this is a competitive industry with rational pricing. Any time there's an uptick in trend, the industry has responded by trying to return to target margins. A big part of that comes from the very short-tail nature of the business and our capacity to reprice. We're a market leader in this space, and we keep leading the way. You saw us do that in dental last year. You saw us enter this year expecting rising incidents, following a few good years, and we built that into our plan and into trend. That's essentially part of how we approach it. The other thing I'd mention is that, from our perspective, the power of diversification matters a great deal for us, right? What that means is that on an account-by-account basis, we typically have a bundle rather than a single product, so we can make that bundle attractive, achieve the right economics at the account level, and secure the rate increases we need, whether in disability or other lines. This strategy very much operates at the account level. But again, to your broader question, we believe pricing will reflect experience. We've certainly been planning for a further uptick in trend in disability and are planning for that next year as well, and that is reflected in our pricing and rate actions.

Tom Gallagher analyst
#20

Understood. Appreciate it. Thanks for taking the follow-up. John, is there anything you can share about where you sit on capital management, specifically regarding possible risk transfer transactions involving MetLife Holdings or possible reinsurance arrangements with Chariot Re? Any fresh updates, or how do you expect that market to develop for you?

John McCallion executive
#21

Yeah, I'd say that, broadly speaking, nothing has really shifted when it comes to risk transfer or making use of Chariot. Just on the Chariot front, I'd note that we keep making progress. In fact, another transaction closed right at the end of the quarter. If you take a step back and consider what we set out to achieve there, we see plenty of appealing opportunities to expand our retirement businesses, and we're able to do so by bringing in third-party capital. That outside capital can generate additional MIM fees for us, so we still view Chariot as a strategic growth opportunity. On the risk transfer front, and maybe Ramy can offer a few insights from his own vantage point, I'd say from where we sit nothing has changed. We keep reviewing and engaging with third parties, but at the same time, there's no urgent need forcing us to act. That said, if attractive opportunities present themselves and we see the markets keep developing, we'd want to capitalize on that. Not sure whether you'd like to add anything, Ramy.

Ramy Tadros executive
#22

No, I think you've covered it well, John. Nothing further from me.

Tom Gallagher analyst
#23

Thanks.

Wes Carmichael analyst
#24

Hey, thank you. Good morning. My first one is about the RIS spread. I believe the base spread declined by roughly a basis point, to 99 basis points, during the quarter, though long-term rates have been somewhat more volatile lately, so I'm curious how you expect the base spread to trend going forward.

John McCallion executive
#25

Yeah. Good morning, Wes. This is John. Maybe I'll begin at a high level. Clearly, in total we're above the range. We came in at 130 basis points for the quarter, so that's up sequentially, and the VII certainly drove the beat, while the core spread stayed very stable inside our 95 to 100 range, the one we've referenced previously, and so it was in line with expectations. Even with rates moving around, I think what we've said is that we keep seeing stability in the spread, and that's probably how we'd view the fourth quarter too. On a core basis, we still believe we ought to land within 95 to 100, so that stability should persist. On the VII side, we're assuming we return to the normal $400 million run rate. That would put us in the $100 million to $120 million range for RIS in 4Q, which implies roughly 11.3%.

Wes Carmichael analyst
#26

All right. Thanks, John. Maybe a bigger-picture question on capital, and it may connect to the VNB and payback period discussion. Looking ahead, I'm curious whether you're seeing any shift in the direction of travel for free cash flow conversion. I know you've set a two-year target of 65%-75% of free cash flow conversion. I'm just wondering whether you're seeing that change in the business, or whether you're considering putting more into organic growth given the opportunity set.

John McCallion executive
#27

Yeah, I think, as you say, there are a few factors to consider. First, let me begin by saying we remain comfortable with the 65%-75% range we've given. The other thing worth highlighting, though, is that we've seen solid growth across all our businesses. As you mentioned, we want to sustain that growth. We believe we can keep up and support that strong, healthy breadth of growth we have while also maintaining our 65%-75% free cash flow ratio. Looking back, I'd say our growth rate as a firm right now is incrementally stronger in totality. Obviously, we have less of a runoff business than we once did. I think all the businesses are generally performing well across the board. Taking all of that into context, capital generation is probably stronger, but our growth is also higher, and we're still maintaining our 65%-75% free cash flow ratio.

Wes Carmichael analyst
#28

Thank you.

Alex Scott analyst
#29

Hey, good morning. I wanted to begin on expenses. I appreciate that you've been outperforming the expense ratio guidance you've put out there. How do you see that playing out as we think about heading into 2027?

Michel Khalaf executive
#30

Yeah. Hey, Alex, Michel here. Honestly, I'd say the cost control we've continued to demonstrate is something we feel very good about. Keep in mind that this year we absorbed a business with a higher expense base, PineBridge, which adds about 50 basis points. Even with that, our expectation is to land under the 12.1 target for the year, and the investments we've made in technology are paying off. AI in particular has served as a multiplier of force, and that should continue in the future. It benefits us on efficiency and also on growth and revenue, which is the reason we favor the expense ratio, the direct expense ratio, as a gauge of the progress being made on that front as well. Broadly speaking, I'd characterize the momentum as good. Going forward, I believe there's an opportunity to continue driving that ratio down; at this point we're holding to the 11.3 ratio we talked about at Investor Day, and that is the ratio for 2029. Should an update be needed, we'll keep you informed.

Alex Scott analyst
#31

Great. That's all useful. Regarding cash flow from the Japanese business specifically — clearly, ESR is in a healthy position, but could you say a little about the cash flow you're seeing from that operation? Some other companies have increased reinsurance to generate somewhat more cash from their Japanese business too. Are there any opportunities for you to do reinsurance there?

John McCallion executive
#32

Yeah. Hey, Alex Scott, this is John. I'll handle that one quickly. First, maybe I'll let Lyndon speak to the growth specifically, but that business has grown tremendously. When you consider the past several years and the way it has continued to progress thanks to innovation and the distribution network we possess, it has been genuinely, genuinely strong and extraordinary. Having said that, we also employ reinsurance internally, and we have been doing that; so our strategy is not really shifting; we are basically maintaining our course; so sometimes we use reinsurance for particular products, and for other products we do not. So I would not claim there is any chance to change what we are doing. It is a continuation of what we are doing.

Alex Scott analyst
#33

Okay. Thank you.

Wilma Burdis analyst
#34

Hey, good morning. Could you break down the returns for the quarter between private equity and venture capital? If you could share the balances as well, that would be useful. And perhaps any color on how you're viewing the VII side going into 4Q. Thanks.

John McCallion executive
#35

Morning, Wilma. Maybe I'll take a step back to start. What I'd really stress is that for us, private equity has always been a long-horizon allocation meant to line up with our longer-dated liabilities; so we've never approached this with a quarterly trading mindset; this is a portfolio diversified broadly, spanning 700 funds, 200 managers, and a range of strategies and vintages. And overall, just from a percentage perspective, our VC portfolio makes up about 25% of our PE portfolio; and we have been a steady investor for decades. So, I think the highlight and the takeaway here is Q3 really shows the payoff of that approach overall. From an overall return perspective, I think in the quarter, we saw an actual return in VC funds above 8%; so it was a very strong return in the quarter. But other funds performed well too. I think on average, the portfolio had, as we said, over 4% return, and so others were above plan as well. Looking ahead, for the year so far we're sitting at roughly $1.5 billion, which means we anticipate landing above the $1.6 billion guidance we gave during the outlook call. That said, at this point we don't have anything much more informative to go on beyond assuming we'll maintain our $400 million quarterly run rate for 4Q. As we get closer, just as we've done before, we'll provide an early update on where things stand by the end of the quarter.

Wilma Burdis analyst
#36

All right, thanks. Next, regarding both the VC and private equity portfolios, could you talk about recent performance and how much came from realized exits versus, I suppose, marks or valuation increases? Any detail, I suppose, on possible AI exposure upside, whatever way you'd like to disclose it. But any views on how AI affects those returns? Thanks.

John McCallion executive
#37

Yes. Broadly, the way it works is marks are the driver, and then within the quarter you get realizations that realize the marks. So at the highest level, I'd simply say this quarter brought more realizations than any other quarter. That's perhaps where I'd begin. I don't have the precise percentage figures, but we were backed. Realizations were at a higher level, yet mark to market in the quarter was also higher. So I think realizations are beginning to pick up, which is a good sign. I'd say that contributed to how the portfolio has done as well. And we also gained from a lot of what you listed; through roughly 10 managers in the portfolio, we hold positions in several of the AI names that have been in the news. That definitely was a plus during the quarter.

Wilma Burdis analyst
#38

Thanks.

Jack Matten analyst
#39

Hi there, good morning. My first question is about RIS, and I have two parts to it. First, does the assumption review affect run rate earnings in any way? And second, for the business lines that lean more toward longevity, has the lower mortality you've experienced changed anything when it comes to return hurdles or pricing for new business?

John McCallion executive
#40

Sure, Jack, I'll take that first one — it's John here. Appreciate the question. Briefly, nothing coming out of the actuarial assumption review would change the ongoing run rate. You can probably see the direction we're moving in, and we've also provided guidance on what we expect for the full year and the fourth quarter, which shows what we consider the run rate to be. I'll pass it over to Ramy for the second question.

Ramy Tadros executive
#41

Yes. Morning, Jack. On pricing — we had a modest actuarial assumption review in RIS, which stems from what we do each year; it's a true-up of our baseline assumptions. When we examine the reviews conducted across the past four years, there were adjustments in both directions—some positive, some negative. On a consolidated basis, the net figure came out positive. We haven't altered our long-range assumptions, which factor in gradual gains in mortality, and nothing has shifted regarding what you might call our hurdle rates or the way we approach pricing.

Jack Matten analyst
#42

Got it, that makes sense. Thank you. My second question is about MIM. Could you give any color on what's driving net flows, plus your outlook for flows or your pipeline over the next several quarters? And on the mix of inflows versus outflows, is there any meaningful difference in fee rate or margin profile from the current mix shift?

John McCallion executive
#43

Yeah. Hey, Jack. It's John again. Thanks for the question. Yeah, let me just begin by saying we're very pleased with how the team has been progressing on integration and execution. We launched the One MetLife brand platform over the summer, so overall we're very pleased; we have seen — while some early results were affected by the transaction-related, you've seen some revenue dis-synergies and some mark to market. As we discussed in the opening remarks, earnings are up 19% year to date. Earnings have been building each quarter, and we expect that to continue. We've seen margins expand in terms of profit margins sequentially. Also, if you take a closer look, you've seen a more profitable mix emerging, and revenue yields are up. On top of that, we've seen the integration accelerate, so some expense synergies have materialized and been realized throughout the year. Overall, on the integration, performing well. On the commercial side, I'd say momentum is strong. Even though we had some outflows on the roll forward there, we've actually won more private mandates than we've had outflows in the quarter. Obviously, private mandates do lag because the AUM builds as those assets are deployed. That was in both our private fixed income and our private credit areas. As for the outflows, those have generally been in more of the public fixed income area. I think overall, stepping back, as we said in the opening remarks, we expect to be within the range this year, and our confidence in hitting our 2027 growth targets remains the same.

Jack Matten analyst
#44

Thank you.

Pablo Singzon analyst
#45

Hi, thanks for speaking to me. Early in the call, I think Michel Khalaf made some comments about PRT timing. Are you referring to a deferral to the fourth quarter, or do you think it's more likely that deals show up next year? I guess the context of the question is that some of your competitors have talked about a catch-up in 4Q, but I'm not sure if your appetite aligns with theirs.

Ramy Tadros executive
#46

Hey, good morning. It's Ramy here. Michel's comment, I'll reiterate it, is broader, right? We have a medium-term outlook for this market that is positive; we think this slowdown year-to-date in terms of volume is just timing. From a structural standpoint, every signal we examine—whether funding levels or the surveys we conduct with corporate plan sponsors about their appetite to de-risk and offload pension obligations—indicates a market with substantial runway remaining. As you're aware, we operate at the lumpy, jumbo end of the market, which will always be lumpy. So we're coming off a year—last year—in which we completed $14 billion of PRTs, and our pipeline this year is back-ended. We have a few additional deals arriving in the quarter. That said, stepping back, we continue to see genuinely positive outlook and momentum for the business, given all the structural reasons I mentioned.

Pablo Singzon analyst
#47

Thank you, Ramy. Moving to the second question: these days M&A is simply more of a hot topic in life insurance, for a range of reasons. So I suppose, could you remind everyone which assets you could be interested in acquiring, and roughly the overall framework you apply when assessing opportunities? Thanks.

Michel Khalaf executive
#48

Yes. Hello, Pablo. This is Michel. Yeah, I would say there is absolutely no change in our philosophy or our approach here. Our first-order priority is continuing to put capital to work behind organic growth, and you can see the way we are doing that at appealing returns and paybacks, and we see plenty of opportunity to keep doing so. M&A is a strategic capability for us, but we are extremely disciplined, and M&A has to meet a high bar, I would say, in terms of how we weigh any transaction against other possible uses of capital, including repurchasing our own shares. The two areas we have discussed as possible areas of interest are, one, asset management. We believe this is a space that will keep consolidating. We are also, in a sense, appealing in terms of what we bring to the table regarding our capabilities, particularly if you consider the broader MetLife; we completed a transaction last year that we are very pleased with, PineBridge. The way we think about this is, we do not need anything transformational; we would be looking at the kinds of assets that can bring an adjacency, a capability, a solution, or solutions that can help speed up our growth trajectory. That is one area. The other area I have mentioned is group. While we do not see any gaps in terms of, we have the widest, deepest product offering, solutions offering in the industry, we are always in conversations with customers to see whether there are things we should consider that matter to them. Beyond that, you would be opportunistic; that is a little bit, in a sense, the approach and the philosophy, which, as I said, is unchanged.

Pablo Singzon analyst
#49

Appreciate it, Michel.

John Hall executive
#50

Many thanks, operator, and thank you everyone for being with us on such a busy morning. Stay well and have a great day.

Operator operator
#51

This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete MetLife, Inc. transcript - plus 131,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to MetLife, Inc. earnings transcripts and 131,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.